comparemela.com

Latest Breaking News On - Carly kenselaar - Page 1 : comparemela.com

Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics

During the last three months, 7 analysts shared their evaluations of Travere Therapeutics (NASDAQ:TVTX), revealing diverse outlooks from bullish t.

Carly-kenselaar
Ed-arce
Piper-sandler
Alex-thompson
Nicole-gabreski
Citigroup
Health-care
Travere-therapeutics-inc
Analyst-firm
Hc-wainwright-co
Travere-therapeutics
Analyst-ratings

Citi says buy this little-known biotech stock with nearly 60% upside

The firm's new price target comes after some positive signals have de-risked the path toward full approval for Travere's Filspari drug.

Carly-kenselaar
Drug-administration
Travere-therapeutics
Analyst-carly-kenselaar
Breaking-news-markets
Travere-therapeutics-inc
Stock-markets
Investment-strategy
Markets
Under-the-radar
Business-news

What's Going On With Travere Therapeutics Stock? - Travere Therapeutics (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ: TVTX) shares are trading higher Tuesday.

Ed-arce
Carly-kenselaar
Travere-therapeutics-inc
Citigroup
New-drug-application
Travere-therapeutics

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2023 Earnings Call Transcript

Operator: Thank you for standing by, and welcome to the Innate Pharma Third Quarter 2023 Financial Results and Business Update.

San-diego
California
United-states
Mondher-mahjoubi
Henry-wheeler
Yigal-nochomovitz
Sonia-quaratino
Frederic-lombard
Carly-kenselaar
Daina-graybosch
Rabib-chaudhury
Amgen

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2023 Earnings Call Transcript

Operator: Good day, and welcome to the Lexicon Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.

United-states
Americans
Yasmeen-rahimi
Jeff-wade
Piper-sandler
Carrie-siragusa
Yigal-nochomovitz
Jeffrey-wade
Carly-kenselaar
Craig-granowitz
Andrew-tsai
Nasdaq

vimarsana © 2020. All Rights Reserved.